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Familial benign hypocalciuric hypercalcemia (FBHH) is an
autosomal dominant trait with high penetrance, clinically mani-
festating a relatively benign, lifelong, persistent hypercalcemia
and hypocalciuria without hypercalcemic related complica-
tions. The calcium-sensing receptor (CaSR) plays an important
role in the regulation of PTH secretion and calcium metabo-
lism. Here we present a family with FBHH of an autosomal
dominant inheritance. A heterozygous mutation of E297K
(GAG AAG, exon 4) of CaSR gene was found in 3 family
members. To our knowledge, it is the first confirmed case of
FBHH with CaSR gene mutation in Korea.
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INTRODUCTION
Familial benign hypocalciuric hypercalcemia
(FBHH) is a rare autosomal dominant disorder
exhibiting benign hypercalcemia, inappropriately
normal parathyroid hormone (PTH) levels and
relative hypocalciuria, thus reflecting partial resis-
tance to the normal effects of extracellular calcium
on parathyroid glands and kidneys.
1 The CaSR is
expressed abundantly in the parathyroid gland,
thyroid C cells, and kidney. The vast majority of
FBHH kindred's have their genetic abnormality
link to chromosome 3q21-24, the locus for the
CaSR gene.
2,3 We report a Korean family with
FBHH carrying a mutation in the CaSR gene.
CASE REPORT
A 38-year-old male admitted to the hospital
because of a known 3 cm sized right renal mass
detected by abdominal ultrasonography in routine
health check up and confirmed by computed
tomography. He underwent right radical nephrec-
tomy and the pathologic report revealed clear cell
type renal cell carcinoma with capsular invasion,
but without distant metastasis. His serum calcium
level was 10.9 mg/dL (normal, 8.8-10.8) at pre-
operative evaluation but was ignored. One year
after surgery for a follow-up visit, he was referred
to the Endocrinology and Metabolism department
due to persistent hypercalcemia. The serum cal-
cium level was 11.1 mg/dL and the inorganic
phosphorus was 3.5 mg/dL (normal, 2.5-4.5). The
serum alkaline phosphatase level was 67 U/L
(normal, 30-120), intact PTH was 32 pg/mL (nor-
mal, 10-65), and urine calcium was 20 mg/day
(normal, 100-300). A ratio of urine calcium creati-
nine clearance was 0.0019. Thyroid and adrenal
hormone levels were normal. There was no
evidence of local recurrence or metastasis of carci-
noma. The bone mineral density of the femoral
neck and lumbar spines performed by dual en-
ergy x-ray absorptiometry (Expert XL, Lunar Co.,
Madison, WI, USA) showed normal (femoral neck
T-score, 1.0; lumbar spines T-score, -0.6). The bio-
chemical and clinical evaluation was consistent
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with FBHH.
Genomic DNA was isolated from whole blood
samples using QIAamp DNA Blood Mini Kit
(Qiagen, Hilden, Germany) after informed consent
was obtained. DNA sequence of CaSR gene of the
proband was analyzed by PCR amplification of all
coding exons of CaSR gene and direct sequencing
of PCR products. Briefly, the PCR amplification
was carried out in a PTC-225 DNA Engine Tetrad
(MJ Research, Waltham, MA, USA). PCR condi-
tion was 94 for 5 minutes for 1 cycle, and 94
for 45s, 60 for 45s, 72 for 120s for 30 cycles and
72 for 5 minutes for 1 cycle using Taq DNA
polymerase (SolGent Co. Daejeon, South Korea).
All of the coding exons (exon 2-exon 7) were an-
alyzed by direct sequencing of PCR products
using an ABI PRISM BigDye kit from Applied
Biosystems. Forward and reverse sequences of
PCR products were produced with an ABI PRISM
3100 Genetic Analyzer (Applied Biosystems, Fos-
ter City, CA, USA).
The result revealed that the proband had a
heterozygous mutation of E297K (GAG AAG,
Glu Lys, nucleotide 889 G A, exon 4) of CaSR
gene (Fig. 1). The 74bp PCR product including
Mnl I site was amplified using the primers CaSR_
RFLP_F (CTCATCAAGGAGATTGTCCGG) and
CaSR_RFLP_R (GAGGAGCTGGCCCAGGC). PCR
amplification was carried out employing the same
method mentioned above. The product of PCR
amplification was digested with 1ul (5U) of Mnl
I enzyme. The digestion occurred for 2 hours at
37 , which was then electrophoretically resolved
in components 2.5% agarose gel in 0.5X TBE. The
result revealed that the proband had a heterozy-
gous loss of an Mnl I site (Fig. 2).
We performed biochemical and clinical evalua-
tion of his family members. The plasma calcium
of his 8-year-old son revealed 10.7 mg/dL, the
inorganic phosphorus was 4.2 mg/dL and PTH
was 56 pg/mL and random urine calcium 1.9 mg/
dl, urine creatinine 82.0 mg/dL, the ratio of urine
calcium creatinine clearance was 0.0013. The same
Fig. 1. The direct sequencing analysis of PCR products of
the proband. The result revealed a heterozygous
mutation of E297K (GAG AAG, exon 4) of CaSR gene.
Fig. 3. Pedigree of the FBHH family. Circles indicate
women, squares indicate men, and arrow indicates the
proband. Hatched symbols represent individuals with
heterozygous E297K mutation.
Fig. 2. Mnl I restriction digest of PCR-amplified DNA
from 5 family members. The individual with FBHH
exhibits heterozygous loss of an Mnl I site, resulting in
the appearance of 74bp fragment derived from the mutant
allele, and 47bp + 27bp fragment derived from the normal
allele.A Case of Congenital Neuromuscular Disease with Uniform Type 1 Fiber
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mutation of codon 297 was found in his son and
his 66-year-old mother. Biochemical and genetic
analysis of his daughter and sister were normal
(Fig. 3).
DISCUSSION
FBHH is a hypercalcemic syndrome usually
characterized by as an asymptomatic and uncom-
plicated hypercalcemia and apparent normal
longevity. The mode of inheritance is autosomal
dominant with high penetrance, affecting both
genders equally. The hypercalcemia is usually
diagnosed at a young age, and it could be diag-
nosed as early as birth if screened for.
4
FBHH is a rare disorder, but it is clinically im-
portant because it can be confused with primary
hyperparathyroidism. The biochemical features of
the two conditions are similar, but the former is
benign while the latter can have serious clinical
consequences with patients occasionally pro-
ceeding to parathyroidectomy.
The serum calcium level (total and ionized) is
usually mildly elevated; values are indistinguish-
able from those of patients with primary hyper-
parathyroidism. Similar to hyperparathyroidism,
serum phosphate levels are normal to slightly de-
creased, but serum magnesium levels are normal
to slightly elevated.
4-7 Abnormal calcium-sensing
in FBHH is reflected in the inappropriately nor-
mal parathyroid hormone (PTH) levels in the
overwhelming majority of patients with FBHH,
whereas over 85% of patients with hyperpara-
thyroidism have elevated PTH levels.
8,9 In FBHH,
1,25-dihydroxyvitamin D levels have been re-
ported to be normal.
5 Urinary indices usually re-
veal relative hypocalciuria for the degree of hyper-
calcemia, pointing to excessively avid tubular
renal calcium reabsorption.
4,5,10 A calcium creati-
nine clearance ratio ([UCa × SCr]/[SCa × UCr])
below 0.01 has been suggested as cut-off values in
patients with FBHH in the absence of other factors
lowering urinary calcium excretion, whereas a
ratio over 0.02 as with hyperparathyroidism.
4,5,10
Kidney function, is normal, as well as urinary
concentrating ability, in contrast to hyperpara-
thyroidism.
4,11
The calcium-sensing receptor (CaSR) is a cell
surface protein that consists of 1078 amino acids
and belongs to the superfamily of the seven-
transmembrane domain, G protein coupled re-
ceptors.
2 Over 90% of FBHH kindred's have their
genetic abnormality linked to chromosome 3q21 -
24, the locus for the CaSR gene.
3 Most mutations
in the CaSR associated with FBHH are single
point mutations (inactivating mutation) localized
in either the region encoding the extracellular
calcium-sensing domain, particularly exon 3 and
4, or the region encoding the signal-transducing
domain, exon.
7
Renal cell carcinoma often shows hypercal-
cemia, so we evaluated the relationship between
renal cell carcinoma and hypercalcemia in this
case. The radiologic findings revealed no evidence
of distant metastasis including bone or local
recurrence. The laboratory findings of the patient
were not relevant to those in the case of malig-
nancy due to elevation of PTHrP, such as hyper-
calcemia, hypophosphatemia, hypercalciuria, and
decreased levels of parathyroid hormone. Von
Hippel Lindau disease (VHL) is an autosomal
dominant familial cancer syndrome.
12 Affected
patients are predisposed to develop central ner-
vous system hemangioblastomas, renal cell carci-
noma, and pheochromocytoma.
12,13 To determine
if a relationship existed between FBHH in this
case and VHL, we analyzed the pedigree and
chromosomes of the family and searched for any
existing organ involvement. The findings demon-
strated that there was no relationship between
FBHH and renal cell carcinoma or between FBHH
and VHL in this case.
Currently, more than 40 inactivating mutations
in the CaSR gene have been identified in patients
with FBHH.
14-18 We report here a Korean family
with FBHH carrying a mutation in the CaSR gene.
The mutation was located in extracellular domain
of CaSR as E297K mutation, which was already
reported by Pollak et al. in 1993.
2 The prevalence
of E297K mutation is not reported, and this is
actually the second case in English literature. The
prevalence of CaSR gene mutation associated with
FBHH is even largely unknown, but is estimated
at 1 of 78,000, at least in Scotland.
19
The mechanism of CaSR insensitivity by E297K
heterozygous mutation was studied in human
embryonic kidney cells. The E297K mutation leadsSeong Ill Woo, et al.
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to formation of heterodimers of CaSR compared
to wild type homodimerization. As a result, extra-
cellular calcium-elicited increase in cytosolic cal-
cium is impaired about 63%.
20 To our knowledge,
it is the first case of FBHH confirmed with CaSR
gene mutation in Korea, and the second case of
E297K mutation in English literature.
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